Anzeige
Mehr »
Login
Montag, 23.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D5YN | ISIN: US6031701013 | Ticker-Symbol:
NASDAQ
20.12.24
21:59 Uhr
12,330 US-Dollar
0,000
0,00 %
1-Jahres-Chart
MINERALYS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
MINERALYS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur MINERALYS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.12.Polar Asset Management Partners Inc. Purchases Shares of 40,500 Mineralys Therapeutics, Inc. (NASDAQ:MLYS)2
12.11.Mineralys Therapeutics CMO verkauft Aktien im Wert von 75.398 US-Dollar1
11.11.Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update46- Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 - - Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering...
► Artikel lesen
MINERALYS THERAPEUTICS Aktie jetzt für 0€ handeln
30.10.Mineralys Therapeutics, Inc. - 8-K, Current Report2
22.10.Mineralys Therapeutics, Inc.: Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 20243
25.09.Mineralys Therapeutics, Inc. - 8-K, Current Report-
25.09.Mineralys Therapeutics, Inc.: Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension125- On track to announce topline data in Q1 2025 - - Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program...
► Artikel lesen
14.08.Mineralys Therapeutics kicks off key program, shares hold buy rating with Stifel1
13.08.Mineralys Therapeutics GAAP EPS of -$0.83 misses by $0.121
13.08.Mineralys Therapeutics, Inc. - 10-Q, Quarterly Report1
13.08.Mineralys Therapeutics, Inc. - 8-K, Current Report1
13.08.Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update98- Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 - - Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to deliver...
► Artikel lesen
14.06.Mineralys Therapeutics, Inc.: Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors134RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
► Artikel lesen
04.01.Mineralys Therapeutics, Inc.: Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer254RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1